DRRX vs. EYEN, FBIO, JAGX, VYNE, CARA, NRXP, UNCY, CASI, LEXX, and HCWB
Should you be buying DURECT stock or one of its competitors? The main competitors of DURECT include Eyenovia (EYEN), Fortress Biotech (FBIO), Jaguar Health (JAGX), VYNE Therapeutics (VYNE), Cara Therapeutics (CARA), NRx Pharmaceuticals (NRXP), Unicycive Therapeutics (UNCY), CASI Pharmaceuticals (CASI), Lexaria Bioscience (LEXX), and HCW Biologics (HCWB). These companies are all part of the "pharmaceutical preparations" industry.
DURECT (NASDAQ:DRRX) and Eyenovia (NASDAQ:EYEN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.
DURECT received 146 more outperform votes than Eyenovia when rated by MarketBeat users. Likewise, 65.15% of users gave DURECT an outperform vote while only 65.13% of users gave Eyenovia an outperform vote.
DURECT has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, Eyenovia has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.
Eyenovia has lower revenue, but higher earnings than DURECT. DURECT is trading at a lower price-to-earnings ratio than Eyenovia, indicating that it is currently the more affordable of the two stocks.
28.0% of DURECT shares are held by institutional investors. Comparatively, 25.8% of Eyenovia shares are held by institutional investors. 4.3% of DURECT shares are held by company insiders. Comparatively, 7.1% of Eyenovia shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, DURECT had 1 more articles in the media than Eyenovia. MarketBeat recorded 7 mentions for DURECT and 6 mentions for Eyenovia. Eyenovia's average media sentiment score of 0.38 beat DURECT's score of 0.32 indicating that Eyenovia is being referred to more favorably in the news media.
Eyenovia has a net margin of 0.00% compared to DURECT's net margin of -279.77%. Eyenovia's return on equity of -322.68% beat DURECT's return on equity.
DURECT currently has a consensus target price of $27.50, indicating a potential upside of 2,100.00%. Eyenovia has a consensus target price of $10.00, indicating a potential upside of 1,338.43%. Given DURECT's higher possible upside, equities research analysts plainly believe DURECT is more favorable than Eyenovia.
Summary
Eyenovia beats DURECT on 9 of the 16 factors compared between the two stocks.
Get DURECT News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
